The South East Asian pharma industry has been growing at an average of 6-10 per cent in the past 10 years. The governments across the ASEAN region are introducing universal healthcare programmes, with the consequential rising demand for all categories of medicines, especially generic drugs
Comprising almost 40 per cent of the SEA economic output, Indonesia is now the largest pharma market in the Southeast Asia/Asia Pacific region (SEA/AP), experiencing an impressive 85 per cent growth in between 2007-2013. The country has the biggest and fastest growing economy in the SEA region and a pharma economy consisting of approximately 200 pharmaceutical companies.
There are already 25-30 generic domestic companies with access to the international market, and equally, there are approximately 35 multinational companies, such as Sanofi, ACG and Novo Nordisk, established in the area. Most significantly however, are the remaining domestic manufacturers, who are increasingly targeting international sales in neighbouring countries.
CPhI South East Asia expo
As regional pharma companies are poised for robust growth in the coming years, CPhI South East Asia, the most important fair of the pharmaceutical industry in Indonesia and throughout Southeast Asia , will be returning to the Jakarta International Expo in Indonesia for its sixth edition from the March 22 to 24, 2017. The slowing pace of global markets and the increasing threat of a new protectionist wave is transforming the outlook of South East Asian manufacturers, which are now shifting their focus towards regional exports. Mirroring this trend, international investors and companies are increasingly looking at more business access in Indonesia and across the entire ASEAN economy.
Furthermore, national and regional governments and regional trade groups, such as the Ministry of Health, Ministry of Industry, Indonesia Investment Coordinating Board, National Agency for Drug and Food Control; are all very supportive of the development of the pharma industry in the ASEAN region and back the opportunities that CPhI South East Asia brings to the regional pharma economy.
These favourable macro trends are reflected at CPhI South East Asia where domestic manufacturers are increasingly attending the event, with a view to opening up sales in international markets. As the biggest pharma event in the ASEAN region, CPhI South East Asia will gather over 5,500 attendees from 41 countries and more than 260 exhibitors from over 25 countries to network, learn and do business for three days.
Companies come from across the pharma spectrum, including pharma ingredients, machinery, packaging, contract manufacturing and health ingredients – the majority of which are from Asian nations, with a large presence from China.
The co-located events
Co-locating this year with P-MEC, InnoPack, and the returning ICSE and Health Ingredients South East Asia, the event welcomes the best pharma ingredients professionals, packaging experts, machinery providers and contract manufacturing as well as nutraceutical companies from across the region.
n ICSE connects the pharmaceutical community with outsourcing solution providers, offering a forum for business development, networking and education.
n InnoPack brings together buyers and suppliers from the packaging and pharmaceutical industries, creating business opportunities through a dedicated worldwide forum.
n P-MEC delivers innovative pharmaceutical machinery, equipment and technology to a worldwide forum of decision makers through face-to-face networking and education.
n Hi South East Asia (Health ingredients South East Asia) is the gateway to South East Asia's health, functional food and beverage and supplements market.
The event’s conference programme is a dedicated, content-enriched platform that will cover business outlook and markets, regulations and compliance, and manufacturing and supply chain. Sessions include “Strategies to improve market access”, “Effective compliance strategies when managing 3rd parties” and “Big Data trends and applications in Supply Chain” and panel discussions on “A look at the pharmaceutical industry in South East Asia” and “ASEAN regulatory harmonization developments”.
CPhI South East Asia provides exhibitors and visitors the opportunity to network, create and nurture new businesses, learn about the ASEAN pharma market, and develop their industry.
To help magnify the event’s reach across the whole ASEAN economy, and therefore the industry’s growth, CPhI South East Asia have expanded database of providers. Using the new Distributor Network, all distributors in the region have been individually invited to visit the event and network with peers and exhibitors.
Another first this year, is the CPhI South East Asia Investment Forum. This exclusive, invitation-only initiative matches key international investors with the top tier pharma companies looking for reliable partners.
Other features
Other features at CPhI South East Asia in 2017 include Business Matchmaking programme and Road shows. The Business Matchmaking programme provides attendees with the opportunity to browse potential clients, schedule meetings before the event, and find new business partners. Road shows have been organized in many ASEAN countries to further promote CPhI South East Asia as a pharma bridge in the region.
The event creates a regional hub and increases opportunities for regional and international exhibitors and visitors to meet with potential partners or investors, be it through the matchmaking programme, the Investment Forum or other initiatives.
ASEAN, India trade
The ASEAN region has a number of companies dedicated to the pharma ingredients sector, but faces cost pressures from many international rivals, thus it is also a heavy importer of APIs. India and Indonesia can benefit from a strong relationship. India can benefit from Indonesia’s strong demand for ingredients, while the Indonesia can take advantage of its own distribution knowledge in the challenging geography.
Bilateral trade between ASEAN and India is expected to reach US$ 280 billion by 2024-2025, creating a wide array of sourcing opportunities for products from India to manufacturers and distributors in ASEAN countries.
Says Rutger Oudejans, Brand Director CPhI South East Asia at UBM EMEA, “2017 marks the 6th anniversary of CPhI South East Asia, and it is incredible to see how far this pharma economy has come and how fast it is developing. We are seeing a strong interest from international companies coming to the event looking to do business not only in Indonesia, but in the entire ASEAN economy. Additionally, in the last few years, more and more Indonesian regional manufacturers are using the event as an essential conduit to begin established sales outside their core domestic market. The establishment of the AEC, the introduction of universal healthcare programmes and hundreds of established domestic manufacturers is fuelling interest in sales across the region. This year we will also introduce the ASEAN-India strategic forum to help increase bilateral trade with Indian counterparts, as well as an Investment Forum and Distributors network.”
CPhI South East Asia 2016
CPhI South East Asia 2016 saw the launch of two sister brands, ICSE and Hi SEA – mirroring the increase in demand and development for health ingredients as well as contract manufacturing in the region. The event hosted over 4300 attendees and more than 250 exhibitors from countries such as China, India, Italy, Korea and the United States.
As the sister of CPhI worldwide, which was founded in 1990 as an international chemical and pharmaceutical trade show, the annually held Jakarta fair has established itself internationally. With the rising standard of living and rising GDP per capita the Indonesian pharmaceutical market develops and provides especially for re-embarking companies tremendous growth opportunities. To facilitate the entry in that market, CPhI South East Asia is the perfect platform, because all the major suppliers and buyers in the chemical and pharmaceutical industry are meeting each other. New trends are set and innovations are presented, networks are developed, contacts and long-term business relationships are established.
All major Indian and Southeast Asian suppliers of pharmaceutical ingredients, outsourcing, equipment and bio-solutions present themselves at the fair. Together with the P-MEC South East Asia and the InnoPack South East Asia, it represents the entire value chain of the pharmaceutical and biotechnology industry and creates incredible synergies in all directions.